丹麦Novo Nordisk制药公司因据称关于增长和竞争的误导性言论而面临诉讼。 Danish drug firm Novo Nordisk faces lawsuit over alleged misleading statements on growth and competition.

丹麦一家制药公司Novo Nordisk面临一项集体诉讼,指控2025年5月7日至7月28日证券欺诈。 Novo Nordisk, a Danish pharmaceutical company, faces a class-action lawsuit alleging securities fraud from May 7 to July 28, 2025. 诉讼主张从复杂的GLP-1药物中误导关于该公司增长潜力和竞争影响的说法。 The lawsuit claims misleading statements about the company's growth potential and impact of competition from compounded GLP-1 drugs. 高盛(Goldman Sachs)认为该公司的长期前景可能不如最近52%的股票下跌所显示的那样暗淡, 尽管Eli Lilly的Mounjaro等竞争对手提出了挑战, Meanwhile, Goldman Sachs believes the company's long-term prospects may not be as bleak as its recent 52% stock decline suggests, despite challenges from competitors like Eli Lilly's Mounjaro and cheaper compounded alternatives. 敦促股东加入诉讼,争取追回损失。 Shareholders are urged to join the lawsuit to seek recovery of losses.